Long-Acting Antipsychotics Tied to Superior Outcomes Long-Acting Antipsychotics Tied to Superior Outcomes
Clozapine and long-acting injectable antipsychotics have the lowest risk for relapse and treatment failure in patients with schizophrenia, a large,'real-world'study shows.Medscape Medical News
Condition: Schizophrenia Interventions: Combination Product: Active tDCS + Auditory Training; Combination Product: Active tDCS + Control Condition; Combination Product: Sham tDCS + Auditory Training Sponsor: VA Greater Los Angeles Healthcare System Not yet recruiting
Accumulating evidence indicates that one-carbon metabolism dysregulation, manifesting in low folate levels and elevated homocysteine levels, frequently occurs in patients with schizophrenia.1 Additionally, it has been found that these metabolic alterations are associated with a higher severity of negative symptoms.2 Previous studies investigating the efficacy of supplementation strategies have found small but significant improvement of negative symptoms that might be influenced by folate-related gene polymorphisms.3 –5
Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has found that communication skills can impact on a person's recall and understanding of the diagnosis, treatment options and prognosis. People may feel confused and perplexed when information about their illness is not communicated properly. Sharing information about diagnosis of a serious mental illness is particularly challenging. The nature of mental illness is often difficult to explain since there may be no clear aetiology, and the treatment options and prognosis may vary enormously. In ad...
The efficacy of chlorpromazine, a benchmark antipsychotic, has not been fully assessed in direct comparison with different individual antipsychotics. Penfluridol is another old antipsychotic with a long half-life so one oral dose may last up to one week. This could confer advantage. To assess the clinical effects of chlorpromazine compared with penfluridol for adults with schizophrenia.
When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. The main objectives of the study were to establish the clinical effectiveness and cost-effectiveness of augmentation of clozapine medication with a second antipsychotic, amisulpride, for the management of treatment-resistant schizophrenia.
Yoga is an ancient spiritual practice that originated in India and is currently accepted in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia as an alternative or adjunctive treatment. To systematically assess the effects of yoga versus non-standard care for people with schizophrenia.
Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia. To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadr...
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses.
Adriano Aquino, Guilherme L. Alexandrino, Paul C. Guest, Fabio Augusto, Alexandre F. Gomes, Michael Murgu, Johann Steiner, Daniel Martins-de-Souza
Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI. To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse.